In another experiment, Allegrini and his team demonstrated that irinotecan, when co-administered with the antiangiogenic drug thrombospondin-1 (TS-1) to nude mice bearing HT-29 cells generated tumor, a significant reduction in the size of the tumor occurs as compared to the control as well as individual treatment. This evidence concerns the gene THBS1 and neoplasm.